1. Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis
- Author
-
Minjong Lee, Yuri Cho, Tae-Hun Kim, A Reum Choe, Ho Soo Chun, Hwi Young Kim, and Kwon Yoo
- Subjects
medicine.medical_specialty ,anticoagulants ,Cirrhosis ,genetic structures ,medicine.drug_class ,liver cirrhosis ,Low molecular weight heparin ,Review ,RC799-869 ,Gastroenterology ,behavioral disciplines and activities ,Internal medicine ,mental disorders ,medicine ,Humans ,In patient ,Molecular Biology ,thrombosis ,Venous Thrombosis ,Hepatology ,business.industry ,Standard treatment ,Anticoagulant ,Vitamin K antagonist ,Diseases of the digestive system. Gastroenterology ,medicine.disease ,Thrombosis ,Portal vein thrombosis ,business ,human activities ,psychological phenomena and processes ,portal vein - Abstract
Although patients with cirrhosis are known to be in a state of “rebalance” in that pro- and anticoagulant factors increase the risk for both bleeding and thrombosis, the prevalence of portal vein thrombosis (PVT) in patients with cirrhosis can be up to 26%. Therefore, physicians should consider anticoagulation for the prevention and management of PVT in patients with cirrhosis who are at high risk of PVT. Vitamin K antagonist or low molecular weight heparin is suggested as the standard treatment for PVT in cirrhosis. With the advent of new direct-acting oral anticoagulants (DOACs), there is a paradigm shift of switching to DOACs for the treatment of PVT in patients with cirrhosis. However, the safety and efficacy of DOACs in the treatment of PVT was not well-known in patients with cirrhosis. Therefore, this review focused on the current knowledge about the efficacy, safety concerns, and hepatic metabolism of DOACs in patients with cirrhosis and PVT.
- Published
- 2021